The clinical-stage biopharmaceutical company provides pharmaceutical preparations and medical information for the treatment of opioid addiction, overdose, and dependence. Enalare Therapeutics also offers agnostic therapeutic breathing stimulants to treat life-threatening acute respiratory depression caused by drug overdose, post-surgery, and other conditions. The company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.